Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7343-7349

  Sabino, Mary Ann C ^a,b   Ghilardi, Joseph R ^a,b   Jongen, Joost L M ^a,b   Keyser, Cathy P ^a,b   Luger, Nancy M ^a,b   Mach, David B ^a,b   Peters, Christopher M ^a,b   Rogers, Scott D ^a,b   Schwei, Matthew J ^a,b   De Felipe, Carmen ^c   Mantyh, Patrick W ^a,b,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VA MEDICAL CENTER   (United States)

^c Univ M H C Sup Invest Cie   (Spain)

^d 18 208 Moos Towers ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[3 (3,4 DIFLUOROPHENYL) 4 (4) METHYLSULFONYL] 2 (5H) FURANONE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CANCER; BONE DESTRUCTION; BONE METASTASIS; BONE REMODELING; BREAST CANCER; CANCER INFILTRATION; CANCER PAIN; CONTROLLED STUDY; DRUG SELECTIVITY; ENZYME INHIBITION; GENE EXPRESSION; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROSTATE CANCER; SARCOMA; TUMOR GROWTH;

ANIMALS; BONE NEOPLASMS; CELL DIVISION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; HYPEROSTOSIS; ISOENZYMES; MALE; MICE; MICE, INBRED C3H; NEURONS, AFFERENT; OSTEOCLASTS; OSTEOSARCOMA; PAIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SPINAL CORD;

EID: 0037115425     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Coleman, R. E. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev., 27: 165-176, 2001.
2. Braun, S., Pantel, K., Muller, P., Janni, W., Hepp, F., Kentenich, C. R. M., Gastroph, S., Wischnik, A., Dimpfi, T., Kindermann, G., Riethmuller, G., and Schlimok, G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Eng. J. Med., 342: 525-533, 2000.
3. Mercadante, S. Malignant bone pain: Pathophysiology and treatment. Pain. 69: 1-18. 1997.
4. Portenoy, R, K., Payne, D., and Jacobsen, P. Breakthrough pain: Characteristics and impact in patients with cancer pain. Pain, 81: 129-134, 1999.
5. Schwei, M. J., Honore, P., Rogers, S. D., Salak-Johnson. J. L., Finke, M. P., Ramnaraine, M. L., Clohisy, D. R., and Mantyh, P. W. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J. Neurosci., 19: 10886-10897, 1999.
6. Honore, P., Luger, N. M., Sabino, M. A., Schwei, M. J., Rogers, S. D., Mach, D. B., O'Keefe, P., F., Ramnaraine, M. L., Clohisy, D. R., and Mantyh, P. W. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat. Med., 6: 521-528, 2000.
7. Luger, N. M., Honore, P., Sabino, M. A. C., Schwei, M. J., Rogers, S. D., Mach, D. B., Clohisy, D. R., and Mantyh, P. W. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res., 61: 4038-4047, 2001.
8. Payne, R. Mechanisms and management of bone pain. Cancer (Phila.), 80: 1608-1613, 1997.
9. Samad, T. A., Moore, K. A., Sapirstein, A., Billet, S., Allchorne, A., Poole, S., Bonventre, J. V., and Woolf, C. J. Interleukin-1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature (Lond.), 410: 471-475, 2001.
10. Zhang, Y., Shaffer, A., Portanova, J., Seibert, K., and Isakson, P. C. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J. Pharmacol. Exp. Ther., 283: 1069-1075, 1997.
11. Julius, D., and Basbaum, A. I. Molecular mechanisms of nociception. Nature (Lond.). 413: 203-210, 2001.
12. Pilbeam, C. C., Harrison, J. R., and Raisz, L. G. Prostaglandins and bone metabolism. In: R. L. G. Bilezikian, and G. A. Rodan (eds.) Principles of Bone Biology, Vol. 2, pp. 979-994. San Diego, CA: Academic Press, 2002.
13. Li, X. D., Okada, Y., Pilbeam, C. C., Lorenzo, J. A., Kennedy, C. R. J., Breyer, R. M., and Raisz, L. G. Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology, 141: 2054-2061, 2000.
14. Raisz, L. G. Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am. J. Med. 110: 43S-45S, 2001.
15. Sheng, H., Shao, J., Kirkland, S. C., Isakson, P., Coffey, R. J., Morrow, J., Beauchamp, R. D., and DuBois, R. N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Investig., 99: 2254-2259, 1997.
16. Sumitani, H., Kamijo, R., Toyoshima, T., Nakanishi, Y., Takizawa, K., Hatori, M., and Nagumo, M. Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E-2 production. J. Oral Pathol. Med., 30: 41-47, 2001.
17. Fosslien, E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit. Rev. Clin. Lab. Sci., 37: 431-502, 2000.
18. Gupta, R. A., and Dubois, R. N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Reviews Cancer, 1: 11-21, 2001.
19. Thun, M. J., Henley, S. J., and Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst., 94: 252-266, 2002.
20. Marnett. L. J., and Kalgutkar, A. S. Cyclooxygenase 2 inhibitors: Discovery, selectivity and the future. Trends Pharmacol. Sci., 20: 465-469, 1999.
21. Honore, P., Rogers, S. D., Schwei, M. J., Salak-Johnson, J. L., Luger, N. M., Sabino, M. C., Clohisy, D. R., and Mantyh, P. W. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience, 98: 585-598, 2000.
22. Oshima M., Dinchuk. J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in APC (δ-716) knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
23. Riendeau, D., Percival, M. D., Brideau, C., Charleson, S., Dube, D., Ethier, D., Falgueyret, J. P., Friesen, R. W., Gordon, R., Greig, G., Guay, J., Mancini, J., Ouellet, M., Wong, E., Xu, L., Boyce, S., Visco, D., Girard, Y., Prasit, P., Zamboni, R., Rodger, I. W., Gresser, M., Ford-Hutchinson, A. W., Young, R. N., and Chan, C. C. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther., 296: 558-566, 2001.
24. Lal, G., Ash, C., Hay, K., Redston, M., Kwong, E., Hancock, B., Mak, T., Kargman, S., Evans, J. F., and Gallinger, S. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-/2 inhibitor. Cancer Res. 61: 6131-6136, 2001.
25. Ouellet, M., Riendeau, D., and Percival, M. D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc. Natl. Acad. Sci. USA, 98: 14583-14588, 2001.
26. Yang, M., Baranov, E., Jiang, P., Sun, F. X., Li, X. M., Li, L., Hasegawa, S., Bouvet, M., Al-Tuwaijri, M., Chishima, T., Shimada, H., Moossa, A. R., Penman, S., and Hoffman, R. M. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc. Natl. Acad. Sci. USA, 97: 1206-1211, 2000.
27. Hunt, S. P., Pini, A., and Evan, G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature (Lond.), 328: 632-634, 1987.
28. Doyle, C. A., and Hunt, S. P. Substance P receptor (neurokinin-1)-expressing neurons in lamina I of the spinal cord encode for the intensity of noxious stimulation: A c-Fos study in rat. Neuroscience, 89: 17-28, 1999.
29. Basbaum, A. I. Immediate-early genes and pain: What's all the "Fos" about? APS Journal, 3: 49-52, 1994.
30. Jasmin, L., Gogas, K. R., Ahlgren, S. C., Levine, J. D., and Basbaum, A. I. Walking evokes a distinctive pattern of Fos-like immunoreactivity in the caudal braistem and spinal cord of the rat. Neuroscience. 58: 275-286, 1994.
31. Abbadie, C., Taylor, B. K., Peterson, M. A., and Basbaum, A. I. Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: Studies with remifentanil and lidocaine. Pain, 69: 101-110. 1997.
32. Mantyh, P. W., DeMaster, E., Malhotra, A., Ghilardi, J. R., Rogers, S. D., Mantyh, C. R., Liu, H., Basbaum, A. I., Vigna, S. R., Maggio, J. E., and et at. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science (Wash. DC), 268: 1629-1632, 1995.
33. Abbadie, C., Trafton, J., Liu, H., Mantyh, P. W., and Basbaum, A. I. Inflammation increases the distribution of dorsal horn neurons that internalize the neurokinin-1 receptor in response to noxious and non-noxious stimulation. J. Neurosci., 17: 8049-8060, 1997.
34. Honore, P., Menning, P. M., Rogers, S. D., Nichols, M. L., Basbaum, A. I., Besson, J-M., and Mantyh, P. W. Spinal substance P receptor expression and internalization in acute, short-term, and long-term inflammatory pain states. J. Neurosci., 19: 7670-7678, 1999.
35. Vanderah, T. W., Ossipov, M. H., Lai, J., Malan, T. P., and Porreca, F. Mechanisms of opioid-induced pain and antinociceptive tolerance: Descending facilitation and spinal dynorphin. Pain, 92: 5-9, 2001.
36. Vanderah, T. W., Laughlin, T., Lashbrook, J. M., Nichols, M. L., Wilcox, G. L., Ossipov, M. H., Malan, T. P., Jr., and Porreca, F. Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: Blockade by MK-801 but not naloxone. Pain, 68: 275-281, 1996.
37. Laughlin, T. M., Vanderah, T. W., Lashbrook, J., Nichols, M. L., Ossipov, M., Porreca, F., and Wilcox, G. L. Spinally administered dynorphin A produces long-lasting allodynia: Involvement of NMDA but not opioid receptors. Pain, 72: 253-260. 1997.
38. Noguchi, K., Kowalski, K., Traub, R., Solodkin, A., Iadarola, M. J., and Ruda, M. A. Dynorphin expression and Fos-like immunoreactivity following inflammation induced hyperalgesia are colocalized in spinal cord neurons. Brain Res. Mol. Brain Res., 10: 227-233, 1991.
39. Iadarola, M. J., Douglass, J., Civelli, O., and Naranjo, J. R. Differential activation of spinal cord dynorphin and enkephalin neurons during hyperalgesia: Evidence using cDNA hybridization. Brain Res., 455: 205-212, 1988.
40. Clohisy, D. R., Ogilvie, C. M., Carpenter, R. J., and Ramnaraine, M. L. Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts. J. Orthopaedic Res., 14: 2-6, 1996.
41. Lees, R. L., and Heersche, J. N. Macrophage colony stimulating factor increases bone resorption in dispersed osteoclast cultures by increasing osteoclast size. J. Bone Miner. Res., 14: 937-945, 1999.
42. Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S, L., Woerner, B. M., Edwards, D. A., Flickinger, A. G., Moore, R. J., and Seibert, K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res., 60: 1306-1311, 2000.
43. Kundu, N., Yang, Q. Y., Dorsey, R., and Fulton, A. M. Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int. J. Cancer, 93: 681-686, 2001.
44. Dubois, R. N., Radhika, A., Reddy, B. S., and Entingh, A. J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology, 110: 1259-1262, 1996.
45. Hingtgen, C. M., Waite, K. J., and Vasko, M. R. Prostaglandins facilitate peptide release from rat sensory neurons by activating the adenosine 3′, 5′-cyclic monophosphate transduction cascade. J. Neurosci., 15: 5411-5419, 1995.
46. Nicol, G. D., Klingberg, D. K., and Vasko, M. R. Prostaglandin E2 increases calcium conductance and stimulates release of substance P in avian sensory neurons. J. Neurosci., 12: 1917-1927, 1992.
47. Sauer, S. K., Bove, G. M., Averbeck, B., and Reeh, P. W. Rat peripheral nerve components release calcitonin gene-related peptide and prostaglandin E-2 in response to noxious stimuli: Evidence that nervi nervorum are nociceptors. Neuroscience, 92: 319-325, 1999.
48. Mach, D. B., Rogers, S. D., Sabino, M. C., Luger, N. M., Schwei, M. J., Pomonis, J. D., Keyser, C. P., Clohisy, D. R., Adams, D. J., O'Leary, P., and Mantyh, P. W. Origins of skeleton pain: Sensory and sympathetic innervation of the mouse femur. Neuroscience, 113: 155-166, 2002.
49. Willingale, H. L., Gardiner, N. J., McLymont, N., Giblett, S., and Grubb, B. D. Prostanoids synthesized by cyclo-oxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability. Br. J. Pharmacol., 122: 1593-604, 1997.
50. Malmberg, A. B., and Yaksh, T. L. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science (Wash. DC), 257: 1276-1279, 1992.
51. Malmberg, A. B., and Yaksh, T. L. Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. J. Pharmacol. Exp. Ther., 263: 136-146, 1992.
52. Mantyh, P. W., Clohisy, D. R., Koltzenburg, M., and Hunt, S. P. Molecular mechanisms of cancer pain. Nature Reviews Cancer, 2: 201-209, 2002.
53. Hunt, S. P., and Mantyh, P. W. The molecular dynamics of pain control. Nature Reviews Neuroscience, 2: 83-91, 2001.
54. Delaisse, J-M., and Vaes, G. Mechanism of mineral solubilizationand matrix degradation in osteoclastic bone resorption. In: B. R. Rifkin and C. V. Gay (eds.). Biology and Physiology of the Osteoclast. pp. 289-314. Ann Arbor: CRC, 1992.
55. Guise, T. A. Molecular mechanisms of osteolytic bone metastases. Cancer (Phila.), 88: 2892-2898, 2000.
56. Hukkanen, M., Konttinen, Y. T., Rees, R. G., Santavirta, S., Terenghi, G., and Polak, J. M. Distribution of nerve endings and sensory neuropeptides in rat meniscus and bone. Int. J. Tissue React., 14: 1-10, 1992.
57. Bjurholm, A., Kreicbergs, A., Brodin, E., and Schultzberg, M. Substance P- and CGRP-immunoreactive nerves in bone. Peptides, 9: 165-171, 1988.
58. Pilbeam, C. C., Harrison, J. R., and Raisz, L. G. Prostaglandins and bone metabolism. In: J. P., Bilezikian, L. G. Raisz, G. A. Rodan (eds.), Principles of Bone Biology, 2nd Ed. vol. 2, pp. 984-985. San Diego. CA: Academic Press, 2002.
59. Tomita, M., Li, X., Okada, Y., Woodiel, F. N., Young, R. N., Pilbeam, C. C., and Raisz, L. G. Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro. Bone (Elmsford), 30: 159-163, 2002.
60. Chikatsu, N., Takeuchi, Y., Tamura, Y., Fukumoto, S., Yano, K., Tsuda, E., Ogata, E., and Fujita, T. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem. Biophys. Res. Commun., 267: 632-637, 2000.
61. Mancino, A. T., Klimberg, V. S., Yamamoto, M., Manolagas, S. C., and Abe, E. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J. Surg. Res., 100: 18-24, 2001.
62. O'Brien, E. A., Williams, J. H. H., and Marshall, M. J. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. Bone (Elmsford), 28: 208-214, 2001.
63. O'Brien, E. A., Williams, J. H. H., and Marshall, M. J. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem. Biophys. Res. Commun., 274: 281-290, 2000.
64. Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., and Penninger, J. M. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (Lond.), 397: 315-323, 1999.
65. Hsu, H. L., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H. L., Elliott, G., Kelley, M. J., Sarosi, I., Wang, L., Xia, X. Z., Elliott, R., Chiu, L., Black, T., Scully, S., Capparelli, C., Morony, S., Shimamoto, G., Bass, M. B., and Boyle, W. J. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA, 96: 3540-3545, 1999.
66. Akhter, M. P., Cullen, D. M., Gong, G., and Recker, R. R. Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. Bone (Elmsford), 29: 121-125, 2001.
67. Thompson, S. W. N., and Tonge, D. Bone cancer gain without the pain. Nat. Med., 6: 504-505, 2000.
68. Sonoshita, M., Takaku, K., Sasaki, N., Sugimoto, Y., Ushikubi, F., Narumiya, S., Oshima, M., and Taketo, M. M. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(γ 716) knockout mice. Nat. Med., 7: 1048-1051, 2001.
69. Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., and DuBois, R. N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Investig., 105: 1589-1594, 2000.
70. Harris, R. E., Alshafie, G. A., Abou-Issa, H., and Seibert, K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res., 60: 2101-2103, 2000.
71. Reddy, B. S., Hirose, Y., Lubet, R., Steele, V., Kelloff, G., Paulson, S., Seibert, K., and Rao, C. V. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res., 60: 293-297, 2000.
72. Davar, G. Endothelin-I and metastatic cancer pain. Pain Medicine. 2: 24-27, 2001.
73. Liu, C. H., Chang, S. H., Narko, K., Trifan, O. C., Wu, M. T., Smith, E., Haudenschild, C., Lane, T. F., and Hla, T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem., 276: 18563-18569, 2001.
74. Jones, M. K., Wang, H., Peskar, B. M., Levin, E., Itani, R. M., Sarfeh, I. J., and Tamawski, A. S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med., 5: 1418-1423, 1999.
75. Pai R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., and Tamawski, A. S. Prostaglandin E-2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med., 8: 289-293, 2002.
76. Peng, J. P., Su, C. Y., Chang, H. C., Chai, C. Y., and Hung, W. C. Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum. Pathol., 33: 100-104, 2002.
77. Chan, G., Boyle, J. O., Yang, E. K., Z. Sacks, P. G., Shah, J. P., Edelstein, D., Soslow, R. A., Koki, A. T., Woerner, B. M., Masferrer, J. L., and Dannenberg, A. J. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res., 59: 991-994, 1999.